As of Aug 29
| +0.03 / +2.01%|
The 1 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 1.55, with a high estimate of 1.55 and a low estimate of 1.55. The median estimate represents a +2.03% increase from the last price of 1.52.
The current consensus among 3 polled investment analysts is to Hold stock in Transition Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.